Format

Send to

Choose Destination
Mult Scler. 2016 Oct;22(12):1541-1549. Epub 2016 Feb 11.

Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.

Author information

1
Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany sven.jarius@med.uni-heidelberg.de.
2
Department of Neuropathology, University Medical Center Göttingen, Göttingen, Germany.
3
Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
4
Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
5
Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Berlin, Germany.
6
Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.

Abstract

BACKGROUND:

Histopathological studies have revealed four different immunopathological patterns of lesion pathology in early multiple sclerosis (MS). Pattern II MS is characterised by immunoglobulin and complement deposition in addition to T-cell and macrophage infiltration and is more likely to respond to plasma exchange therapy, suggesting a contribution of autoantibodies.

OBJECTIVE:

To assess the frequency of anti-myelin oligodendrocyte glycoprotein (MOG), anti-M1-aquaporin-4 (AQP4), anti-M23-AQP4, anti-N-methyl-d-aspartate-type glutamate receptors (NMDAR) and 25 other anti-neural antibodies in pattern II MS.

METHODS:

Thirty-nine serum samples from patients with MS who had undergone brain biopsy (n = 24; including 13 from patients with pattern II MS) and from histopathologically non-classified MS patients (n = 15) were tested for anti-MOG, anti-M1-AQP4, anti-M23-AQP4, anti-NMDAR, anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-type glutamate receptors (AMPAR), anti-gamma-aminobutyric acid receptors (GABABR), anti-leucine-rich, glioma-activated protein 1 (LGI1), anti-contactin-associated protein 2 (CASPR2), anti-dipeptidyl-peptidase-like protein-6 (DPPX), anti-Tr/Delta/notch-like epidermal growth factor-related receptor (DNER), anti-Hu, anti-Yo, anti-Ri, anti-Ma1/Ma2, anti-CV2/collapsin response mediator protein 5 (CRMP5), anti-glutamic acid decarboxylase (GAD), anti-amphiphysin, anti-Ca/RhoGTPase-activating protein 26 (ARHGAP26), anti-Sj/inositol-1,4,5-trisphosphate receptor 1 (ITPR1), anti-Homer3, anti-carbonic anhydrase-related protein (CARPVIII), anti-protein kinase gamma (PKCgamma), anti-glutamate receptor delta 2 (GluRdelta2), anti-metabotropic glutamate receptor 1 (mGluR1) and anti-mGluR5, as well as for anti-glial nuclei antibodies (AGNA) and Purkinje cell antibody 2 (PCA2).

RESULTS:

Antibodies to MOG belonging to the complement-activating immunoglobulin G1 (IgG1) subclass were detected in a patient with pattern II MS. Detailed brain biopsy findings are shown.

CONCLUSION:

This is the largest study on established anti-neural antibodies performed in MS so far. MOG-IgG may play a role in a small percentage of patients diagnosed with pattern II MS.

KEYWORDS:

Multiple sclerosis; N-methyl-d-aspartate type glutamate receptors; aquaporin-4; autoantibodies; biopsy; complement; contactin-associated protein 2; dipeptidyl-peptidase-like protein-6; glioma-activated protein 1; histopathology; leucine-rich; metabotropic gamma-aminobutyric acid receptors; myelin oligodendrocyte glycoprotein; neuropathology; pattern II; voltage-gated potassium channels; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-type glutamate receptors

PMID:
26869529
DOI:
10.1177/1352458515622986
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center